Myriad Genetics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Myriad Genetics, Inc.
News We’re Watching: Medtronic Kickbacks Case, BARDA Contract For Cue, Imeka Neuroimaging Software Cleared
This week, a court ordered a Medtronic whistleblower to hand over records of his media contacts; Cue Health was awarded $28m to develop a multi-disease respiratory panel; and the FDA granted a zero fluoroscopy Indication to some Biosense Webster cardiac ablation devices.
Justices question what Amgen’s invention covers in its dispute with Sanofi. They appear inclined to uphold Federal Circuit’s standard for enablement despite potential negative impact on genus claims.
Coming up after Lilly’s Olumiant and Pfizer’s ritlecitinib in alopecia areata, deuterated ruxolitinib is said to offer a differentiated profile including patient-reported outcomes data.
Public Company Edition: Prime Medicine raised $175m, making its offering the sixth-largest out of 19 biopharma IPOs in the US this year. Also, Oculis and AUM opted to go public via SPAC mergers, Insmed raised $775m from multiple financings and Dice capitalized on positive data with a $300m offering.
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Other Names / Subsidiaries
- Assurex Health
- Counsyl, Inc.
- Crescendo Bioscience
- Myriad Genetic Laboratories, Inc.
- Myriad Pharmaceuticals
- Myriad RBM
- Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG
- Rules Based Medicine
- Sividon Diagnostics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.